Core Viewpoint - Aimeson has submitted a listing application to the Hong Kong Stock Exchange, with joint sponsors being CCB International and Bank of Communications International [1] Company Summary - Aimeson is a leading early cancer detection company focused on high incidence and high mortality cancers, having developed a methylation-based early cancer detection technology [1] - The company's core products include Aixin Gan for liver cancer and Aiguang Le for urinary tract cancer, with Aixin Gan being the world's first liver cancer detection reagent based on methylation and qPCR technology, achieving a sensitivity of 84.43% for stage I liver cancer [1] - Aiguang Le allows for non-invasive detection of urinary tract cancer using just 1 milliliter of urine, enhancing efficiency and convenience [1] - Aimeson has a comprehensive early cancer detection platform covering multiple cancers, including colorectal, liver, esophageal, urinary tract, gastric, lung, and gynecological cancers, and is developing several combination detection reagents [1] Industry Summary - The Chinese tumor molecular testing market is rapidly growing, with an expected market size of 38.8 billion RMB by 2033 [1] - Aimeson employs cost-effective qPCR technology combined with proprietary iTBFinder platform, AS-Cap technology, and SEM-PCR technology to enhance detection capabilities [1] - The company is developing an automated sample processing workstation, AMStation, to support large-scale testing [1]

Core Viewpoint - Wuhan Aimesen Life Science Technology Co., Ltd. has submitted its listing application to the Hong Kong Stock Exchange, focusing on early cancer detection technologies and addressing unmet clinical needs in China [1][3]. Company Overview - Aimesen is a leading early cancer detection company that has developed methylation-based early cancer detection technologies, with two core products: Aixin Gan for liver cancer and Aiguang Le for urinary tract cancer [3][4]. - Aixin Gan is the world's first liver cancer detection reagent based on methylation technology, achieving a sensitivity of 92.33% and specificity of 93.35%, with a sensitivity of 84.43% for stage I patients [3][4]. - Aiguang Le allows non-invasive detection of urinary tract cancer using just 1 milliliter of urine, significantly improving efficiency and convenience compared to traditional methods [3][4]. Market Opportunity - The company is targeting the rapidly growing tumor molecular testing market in China, which is expected to grow from RMB 4.3 billion in 2019 to RMB 8.7 billion by 2024, with a compound annual growth rate (CAGR) of 15.2% [4]. - The market is projected to reach RMB 38.8 billion by 2033, with a CAGR of 18.1% from 2024 to 2033 [4]. Product Development and Innovation - Aimesen has developed a comprehensive early cancer detection platform with a rich product pipeline covering major cancer types, including colorectal, liver, and esophageal cancers, and is expanding into other areas such as gastric, lung, and gynecological cancers [5]. - The company is utilizing cost-effective qPCR technology supported by its proprietary iTBFinder platform, enhancing detection capabilities through innovative techniques [5]. - Aimesen is also developing the AMStation, an automated sample processing workstation, to streamline operations and support large-scale testing [6]. Financial Performance - For the fiscal years ending June 30, 2023, 2024, and 2025, Aimesen reported revenues of RMB 6.233 million, RMB 7.238 million, and RMB 6.513 million, respectively, with significant operating losses [6][10]. - The company incurred operating losses of RMB 49.305 million, RMB 23.788 million, and RMB 6.199 million for the same periods, indicating a challenging financial landscape [10].